Tag Archives: Hemlibra

Sanofi’s Eloctate, a Bioverativ buyout centerpiece, suffers on Roche’s Hemlibra launch

Sanofi has been among the pharma companies hardest hit by U.S. pricing pressure in diabetes, and now, competition is taking a toll on a prized asset from its $ 11.6 billion Bioverativ buyout. In the first quarter, hemophilia drug Eloctate’s sales of €174 missed consensus estimates of €204 million by 14.7%, ODDO BHF analysts wrote in… Read More »